Drug · CHEMBL980

GUAIFENESIN

7 sourcespipelines-2026-09-18-0.3.1

Cite this record

ConductScience Library. GUAIFENESIN. Drugs and targets, record CHEMBL980. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL980

On this page

Drug

Names and IDs as ChEMBL gives them, through Open Targets.

Name: GUAIFENESIN; ChEMBL
ChEMBL ID: CHEMBL980; ChEMBL
Type: Small molecule; ChEMBL
Brand names: Amonidron, Famel, Franolyn chesty, Gecolate, Glycerol guaiacolate, Guaifenesin component of flowtuss, Guaifenesin component of hycofenix, Guaifenesin component of mucinex d, Guaifenesin component of mucinex dm, Guaifenesin component of obredon, Guaifenesin component of xtrelus, Liqufruta, Mucinex, Nirolex for chesty cough decongestant, Tixylix chesty cough; ChEMBL
Other names: CVT-2534, Glyceryl guaiacolate, Guaiacol glyceryl ether, Guaifenesina, Guaifenesine, Guaifensin, Guaiphenesin, Humabid, Hustosil, Methphenoxydiol, NSC-62112, Robitussin; ChEMBL
DrugBank: DB00874; DrugBank
InChIKey: HSRJKNPTNIJEKV-UHFFFAOYSA-N; ChEMBL
Open Targets' highest stage: Approval, for 8 of its 14 diseases, from DailyMed; Open Targets

Targets0

The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.

None in this release.

Diseases14

The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Disease	Open Targets' stage	Stage reported by	Reports	Of them trials	Its drugs
Cough	Approval	DailyMed	74	4	https://conductscience.org/library/drugs?q=HP_0012735
Recurrent upper respiratory tract infections	Phase 3	ClinicalTrials.gov	2	2	https://conductscience.org/library/drugs?q=HP_0002788
common cold	Approval	DailyMed	44	1	https://conductscience.org/library/drugs?q=MONDO_0005709
Acute bronchitis	Unknown	ClinicalTrials.gov	1	1	https://conductscience.org/library/drugs?q=HP_0012388
Infertility	Unknown	ClinicalTrials.gov	1	1	https://conductscience.org/library/drugs?q=HP_0000789
bronchitis	Unknown	ClinicalTrials.gov	1	1	https://conductscience.org/library/drugs?q=MONDO_0003781
chronic rhinitis	Phase 2	ClinicalTrials.gov	1	1	https://conductscience.org/library/drugs?q=MONDO_0004514
pneumonia	Unknown	ClinicalTrials.gov	1	1	https://conductscience.org/library/drugs?q=MONDO_0005249
Nasal congestion	Approval	DailyMed	49	0	https://conductscience.org/library/drugs?q=HP_0001742
Headache	Approval	DailyMed	35	0	https://conductscience.org/library/drugs?q=HP_0002315

1 to 10 of 14Source Open Targets

See all 14 diseases

Trials34

Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs.

Trial	Title	Phase	Participants	Results first posted	Named as	Linked by	Source
NCT01537081	Safety and Efficacy of Mucinex and IR Guaifenesin the Treatment of Symptoms of Acute Upper Respiratory Tract Infections	Phase 2/3	2,810	2013-09-12	guaifenesin	Its name	ClinicalTrials.gov
NCT01202279	Safety and Efficacy Study of Guaifenesin and Pseudoephedrine for Symptomatic Therapy to Treat Acute RTI	Phase 4	1,179	2012-11-05	guaifenesin	Its name	ClinicalTrials.gov
NCT03725085	Study to Evaluate the Safety and Tolerability of Mucinex™(Guaifenesin) 600 mg Extended-Release Bi-Layer Tablets in the Treatment of Otherwise Healthy Patients With Symptoms of Cough, Thickened Mucus and Chest Congestion	Phase 4	552	2019-03-19	guaifenesin	Its name	ClinicalTrials.gov
NCT01046136	Mucinex Exploratory Cold Study	Phase 2	378	2012-08-24	guaifenesin	Its name	ClinicalTrials.gov
NCT01062256	Study of Count Coughs in Subjects With Acute Upper Respiratory Tract Infections		265	2011-03-04	guaifenesin	Its name	ClinicalTrials.gov
NCT00377403	Treatment of Acute Sinusitis	Phase 4	172	2011-06-29	guaifenesin	Its name	ClinicalTrials.gov
NCT01562548	Exploratory Efficacy Study of Guaifenesin in Upper Back Pain		78	2014-06-03	guaifenesin	Its name	ClinicalTrials.gov
NCT01576809	Warming Sensation Intensity and Acceptability of the Flavour, Local Tolerability of Paracetamol 500 mg + Phenylephrine 10mg + Guaifenesin 200 mg Syrup in Patients Suffering a Upper Respiratory Tract Infection (URTI)	Phase 3	51	2013-11-11	guaifenesin	Its name	ClinicalTrials.gov
NCT01114581	Evaluating the Effect of Mucinex 1200mg on Mucociliary and Cough Clearance During an Acute Respiratory Infection	Phase 2	38	2012-10-08	guaifenesin	Its name	ClinicalTrials.gov
NCT03649750	Mucinex® ER 600 mg Bi-Layer Tablet Fed and Fasted	Phase 1	36	2019-02-22	guaifenesin	Its name	ClinicalTrials.gov

1 to 10 of 34

See all 34 trials

Comparisons in its trials15

Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Mucinex D vs Placebo: serious adverse events	0 of 593	0 of 591	1,184	NCT01202279	Trial comparisons
Mucinex D vs Placebo: Antibiotic Sparing	89 of 510	121 of 523	1,033	NCT01202279	Trial comparisons
Mucinex vs Placebo: Number of Patients With Adverse Events	12 of 188	6 of 189	377	NCT01046136	Trial comparisons
Mucinex vs Placebo: serious adverse events	1 of 188	0 of 189	377	NCT01046136	Trial comparisons
Mucinex vs Placebo: Investigator's End of Study Assessment of Treatment	163 of 178	149 of 180	358	NCT01046136	Trial comparisons
Intervention Arm vs Symptomatic Treatments Only: serious adverse events	0 of 85	0 of 81	166	NCT00377403	Trial comparisons
Treatment A: Mucinex® 600 mg (Fast) vs Treatment B: Mucinex® 600 mg (Fed): deaths from any cause	0 of 36	0 of 36	72	NCT03649750	Trial comparisons
Treatment A: Mucinex® 600 mg (Fast) vs Treatment B: Mucinex® 600 mg (Fed): serious adverse events	0 of 36	0 of 36	72	NCT03649750	Trial comparisons
Test (Treatment A) vs Reference (Treatment B): deaths from any cause	0 of 30	0 of 30	60	NCT03644095	Trial comparisons
Test (Treatment A) vs Reference (Treatment B): serious adverse events	0 of 30	0 of 30	60	NCT03644095	Trial comparisons

1 to 10 of 15

See all 15 comparisons in its trials

Papers from its trials8

The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
31632154	DERIVED	1	PubMed
30832720	DERIVED	2	PubMed
28761581	DERIVED	1	PubMed
26462765	DERIVED	1	PubMed
24003241	DERIVED	1	PubMed
23270519	DERIVED	1	PubMed
22337680	DERIVED	1	PubMed
21844413	DERIVED	1	PubMed

Tests in its trials0

The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.

None in this release.

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
ClinicalTrials.gov: 2026-11-05; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
Papers the trials list, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
Tests named in the trials, as ScienceGraph matched them: 2026-11-12; ConductCognition

Sources 7

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ConductCognition's list of its testsOur own data
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this drug from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/drugs/v1/CHEMBL980

GET https://conductscience.org/api/drugs/v1/CHEMBL980/trials?page=2

API reference For AI assistants